Asharq Al-awsat English https://aawsat.com/english Middle-east and International News and Opinion from Asharq Al-awsat Newspaper http://feedly.com/icon.svg

AstraZeneca Antibody Drug Works to Prevent COVID-19 in Longer-term Studies

AstraZeneca Antibody Drug Works to Prevent COVID-19 in Longer-term Studies

Thursday, 18 November, 2021 - 08:00
A test tube labeled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020. (Reuters)

AstraZeneca said on Thursday its COVID-19 antibody drug was 83% effective in cutting the risk of people contracting symptomatic illness in a six-month follow-up study, cementing the drugmaker's lead in developing preventative coronavirus treatments.


The Anglo-Swedish company said a separate study in patients with mild-to-moderate COVID-19 showed that a higher dose of the therapy, AZD7442, cut the risk of symptoms worsening by 88% when given within three days of first symptoms, Reuters reported.


The latest round of positive results potentially position AstraZeneca as a rare supplier of both COVID-19 vaccines and treatments, with the drugmaker having said the therapy's "real advantage" was as a preventative shot, rather than as a treatment.


Editor Picks

Multimedia